Related by context. All words. (Click for frequent words.) 72 axitinib 72 HER2 positive metastatic breast 72 ASA# 71 aflibercept 71 phase IIb clinical 71 afatinib 71 Amrubicin 71 picoplatin 70 custirsen 70 ELACYT 70 EndoTAG TM -1 70 HGS ETR1 70 elotuzumab 69 sunitinib malate 69 INCB# [001] 69 Phase Ib clinical 69 Troxatyl 69 TELCYTA 69 Telcyta 69 vandetanib 69 platinum refractory 69 temsirolimus 69 phase IIa clinical 69 adecatumumab 69 pomalidomide 68 CIMZIA TM 68 relapsed multiple myeloma 68 lintuzumab 68 docetaxel chemotherapy 68 CR# vcMMAE 68 BAY #-# 68 Phase 2b clinical 68 Aplidin 68 Archexin 68 Phase IIb clinical 68 forodesine 68 CA4P 68 pain palliation 68 Phase Ib 68 L BLP# 68 registrational trial 68 Dacogen injection 68 Cloretazine R VNP#M 68 Allovectin 7 68 mapatumumab 68 Marqibo 68 ixabepilone 68 Phase 1b 68 alvespimycin 67 BRIM2 67 refractory AML 67 HRPC 67 FOLOTYN 67 HuMax EGFr 67 enzastaurin 67 talactoferrin 67 mRCC 67 IMGN# 67 brentuximab vedotin SGN 67 Panzem R NCD 67 rindopepimut 67 panitumumab 67 Asentar 67 oral ridaforolimus 67 dacetuzumab 67 Azedra 67 ZACTIMA 67 Phase 2b study 67 elacytarabine 67 seliciclib 67 sapacitabine 67 placebo controlled Phase 67 bosutinib 67 abiraterone acetate 67 velafermin 67 tesmilifene 67 ganetespib 67 Alocrest 67 perifosine 67 Targretin 67 metastatic renal cell carcinoma 67 phase IIb 67 metastatic CRC 66 IMC A# 66 ularitide 66 AP# [003] 66 YONDELIS 66 tanespimycin 66 EndoTAGTM 1 66 cetuximab Erbitux 66 hormone refractory prostate cancer 66 Cloretazine ® 66 PXD# 66 Ocrelizumab 66 AEGR 66 Bezielle 66 IRX 2 66 FOLFIRI 66 huC# DM4 66 motesanib 66 dose cohort 66 lorvotuzumab mertansine 66 blinatumomab 66 eltrombopag 66 non metastatic osteosarcoma 66 Tavocept 66 CoFactor 66 Telintra 66 Corlux 66 belinostat 66 deforolimus 66 zalutumumab 66 Vectibix 66 randomized Phase 2b 66 HGS ETR2 66 PLK1 SNALP 66 RG# [001] 66 nab paclitaxel 66 neratinib 66 pertuzumab 66 iniparib 66 Phase Ib II 66 Phase 2a trial 66 carboplatin paclitaxel 66 pralatrexate 66 APPRAISE 66 Stimuvax 66 satraplatin Phase 66 PEG SN# 66 LymphoStat B 66 valopicitabine 66 T DM1 66 YERVOY 66 phase Ib 66 Phase IIa trial 66 GVAX 66 decitabine 66 L MTP PE 66 celgosivir 65 Phase IIa clinical 65 sunitinib 65 PSMA ADC 65 gefitinib Iressa 65 Azixa 65 rNAPc2 65 viral kinetic 65 Fludara 65 relapsed SCLC 65 ProSavin 65 Aflibercept 65 lupus nephritis 65 romidepsin 65 plus gemcitabine 65 ofatumumab 65 ASONEP 65 TNFerade 65 Perifosine 65 JAK inhibitor 65 Zerenex 65 VELCADE melphalan 65 Genasense 65 Folotyn 65 docetaxel 65 voreloxin 65 Amigal 65 dirucotide 65 FOLOTYN ® 65 Cloretazine 65 Taxotere ® 65 dose cohorts 65 NP2 Enkephalin 65 MAGE A3 ASCI 65 VEGF Trap 65 oral deforolimus 65 IL# PE#QQR 65 Fibrillex TM 65 Ozarelix 65 GRN# 65 TELINTRA 65 ISIS # 65 APOPTONE 65 cilengitide 65 Virulizin ® 65 registrational 65 azacitidine 65 FOLFOX4 65 metastatic renal cell 65 trastuzumab DM1 T DM1 65 IV NSCLC 65 imetelstat 65 assessing T DM1 65 obatoclax 65 Reolysin 65 satraplatin 65 TTF Therapy 65 Phase #b/#a clinical 65 ocrelizumab 65 dexanabinol 65 EFAPROXYN 65 Nuvion 65 TACI Ig 65 nalbuphine ER 65 randomized Phase 65 heavily pretreated 65 CINTREDEKIN BESUDOTOX 65 anti leukemic 65 Xanafide 65 Phase Ib study 65 Glufosfamide 65 Phase IIIb clinical 65 OncoVEX GM CSF 65 SinuNase 65 XL# [003] 65 IMA# 64 NATRECOR R 64 systemic ALCL 64 Xcytrin 64 Proxinium TM 64 recurrent GBM 64 pazopanib 64 Doxil ® 64 Phase IIB 64 elagolix 64 SUCCEED trial 64 ZYBRESTAT 64 Mipomersen 64 rALLy clinical trial 64 CIMZIA ™ 64 phase IIa 64 relapsed refractory multiple myeloma 64 vemurafenib 64 RSR# 64 chlorambucil 64 figitumumab 64 Advexin 64 metastatic hormone refractory 64 Pemetrexed 64 Neuradiab 64 samalizumab 64 Ceflatonin 64 Aurexis 64 LUX Lung 64 lymphoma CTCL 64 MEND CABG II 64 R#/MEM # 64 PROMACTA 64 baminercept 64 Ixempra 64 NLX P# 64 Insegia 64 standard chemotherapy regimen 64 Onconase 64 GAMMAGARD 64 gemcitabine chemotherapy 64 AQ4N 64 Viramidine 64 OPAXIO 64 Hepatocellular Carcinoma HCC 64 Allovectin 7 ® 64 romiplostim 64 depsipeptide 64 sargramostim 64 MyVax personalized immunotherapy 64 ponatinib 64 randomized Phase IIb 64 metaglidasen 64 recurrent glioblastoma multiforme 64 CEQ# 64 ruboxistaurin 64 Phase 1b clinical 64 Phase 2a clinical 64 Fx #A 64 AEG# 64 low dose cytarabine 64 GALNS 64 Plicera 64 metastatic HRPC 64 gemcitabine 64 ISTODAX 64 metastatic colorectal cancer 64 follicular NHL 64 triphendiol 64 pivotal Phase III 64 XGEVA 64 pegloticase 64 SUTENT 64 Tocosol Paclitaxel 64 cancer mCRC 64 bicifadine 64 palifosfamide 64 Chemophase 64 neurologic progression 64 RDEA# 64 HuLuc# 64 Vitaxin 64 plus dexamethasone 64 evaluating tivozanib 64 Tarceva TM 64 teduglutide 64 Golimumab 64 angiographic outcomes 64 dosing cohort 64 recurrent NSCLC 64 nilotinib 64 alvimopan 64 Omacetaxine 64 refractory CTCL 64 Imprime PGG 64 Phenoptin 64 eculizumab 64 investigational monoclonal antibody 64 vosaroxin 64 UPLYSO 64 ridaforolimus 64 VELCADE 63 phase 2a 63 EOquin TM 63 antibody MAb 63 Velcade bortezomib 63 Pralatrexate 63 RSD# oral 63 refractory multiple myeloma 63 PEG PAL 63 Panzem 63 sorafenib Nexavar 63 daclizumab 63 Cotara 63 teriflunomide 63 Phase IIb trials 63 cabazitaxel 63 MGCD# [001] 63 mg kg dose 63 Allovectin 7 R 63 CTAP# Capsules 63 Ceflatonin R 63 oral FTY# 63 Pimavanserin 63 ELND# 63 OXi# 63 dexpramipexole 63 STRIDE PD 63 phase IIb study 63 dasatinib 63 Phase 2b trial 63 urocortin 2 63 Phase #b/#a 63 Fodosine 63 Sym# 63 Vandetanib 63 sorafenib Nexavar ® 63 docetaxel Taxotere ® 63 XL# SAR# 63 docetaxel Taxotere R 63 riociguat 63 Tyrima 63 Folfox 63 vidofludimus 63 evaluable patients 63 cediranib 63 alemtuzumab Campath 63 cell lymphoma CTCL 63 Jevtana 63 PROSTVAC VF 63 Phase IIa 63 Pixantrone 63 TORISEL 63 Trastuzumab 63 dimebon 63 Phase 1a 63 Carfilzomib 63 mCRC patients 63 EGFR expressing 63 LymphoStat B belimumab 63 BRIM3 63 pegylated liposomal doxorubicin 63 FOLPI 63 refractory gout 63 trastuzumab DM1 63 pegylated interferon alpha 63 Bicifadine 63 Vicinium TM 63 Zybrestat 63 MGd 63 LCP Tacro 63 confirmatory Phase III 63 efficacy endpoint 63 phase IIb trial 63 methylnaltrexone 63 lintuzumab SGN 63 GSK# [001] 63 Canvaxin 63 vicriviroc 63 multiple myeloma MM 63 FOLFOX chemotherapy 63 BCIRG 63 lumiliximab 63 relapsed ovarian cancer 63 metastatic castration resistant 63 pemetrexed 63 KNS # 63 lapatinib Tykerb 63 cangrelor 63 brivaracetam 63 KRAS status 63 multicenter Phase 63 plus prednisone 63 talabostat 63 Virulizin R 63 Traficet EN 63 Randomized Phase 63 Genasense ® 63 MDV# 63 heavily pretreated patients 63 cetuximab Erbitux R 63 Trofex 63 cintredekin besudotox 63 Phase IIa clinical trials 63 amrubicin 63 Cimzia TM 63 ILUVIEN ® 63 radiation sensitizer 63 monotherapy 63 CBLC# 63 histone deacetylase HDAC inhibitor 63 PROVENGE 63 maribavir 63 mg/m2 dose 63 refractory Hodgkin lymphoma 63 FOLFOX 63 clevidipine 63 carfilzomib 63 NSCLC 63 lomitapide 63 Satraplatin 63 ACTEMRA TM 63 Quinamed 63 pharmacokinetic PK study 63 HspE7 63 Taxotere R 63 Phase 2a 63 Phase III clinical 63 PSN# [002] 63 HuMax CD4 63 GetGoal Phase III 63 KRN# 63 Androxal TM 62 PEG Interferon lambda 62 tafamidis 62 MYDICAR 62 CD# antibody [001] 62 goserelin 62 pharmacokinetic PK 62 metastatic castrate resistant 62 Pivotal Phase III 62 oral prodrug 62 VAPRISOL 62 REOLYSIN ® 62 peginesatide 62 HCD# [002] 62 EGFR TKI 62 Phase #/#a trial 62 unique alkylating agent 62 Phase 1a clinical 62 crizotinib PF # 62 galiximab 62 clodronate 62 preclinically 62 ZOLINZA 62 PRT# 62 relapsed MM 62 Onrigin 62 Phase IIb 62 elesclomol 62 castrate resistant prostate cancer 62 mipomersen 62 Ostarine 62 albinterferon alfa 2b 62 Capesaris 62 MyVax 62 IV metastatic melanoma 62 BCX# 62 recurrent glioblastoma 62 Brentuximab Vedotin SGN 62 Nicole Onetto MD 62 vinorelbine 62 Vectibix monotherapy 62 bortezomib 62 oblimersen 62 EOquin 62 comparator arm 62 Exherin TM 62 PRX # 62 farletuzumab 62 regorafenib 62 visilizumab 62 adalimumab Humira 62 investigational humanized monoclonal antibody 62 PS# [001] 62 Phase 2b 62 ON #.Na 62 ZYBRESTAT fosbretabulin 62 evaluating Prochymal 62 6R BH4 62 leukemia AML 62 hA# 62 brentuximab vedotin 62 Free Survival PFS 62 dose escalation Phase 62 castration resistant prostate cancer 62 multicenter Phase II 62 biologic therapy 62 secondary efficacy endpoints 62 antiangiogenic therapy 62 OHR/AVR# 62 Phase Ia 62 VIDAZA 62 mertansine 62 Desmoteplase 62 ONTAK 62 iclaprim 62 mitoxantrone 62 BRAF inhibitor 62 prostate cancer CRPC 62 dose escalation trial 62 advanced NSCLC 62 Temsirolimus 62 Vidaza 62 PDX pralatrexate 62 zanolimumab 62 refractory metastatic 62 ongoing Phase 1b 62 bevacizumab Avastin 62 dasatinib Sprycel ® 62 Æterna Zentaris 62 Northera 62 Pivotal Phase 62 Bronchitol 62 ATL# [001] 62 Apoptone 62 DASISION 62 Vidaza azacitidine 62 HGS# 62 LymphoStat B TM 62 refractory PTCL 62 cytokine refractory 62 Xcellerated T Cells 62 cabozantinib 62 Clolar 62 TG# [003] 62 OMAPRO 62 Tesmilifene 62 Clolar ® 62 Elotuzumab 62 OvaRex 62 Phase 1b trial 62 Phase IIb trial 62 ancrod 62 TMC# [002] 62 5-FU/LV 62 Tarceva erlotinib 62 eniluracil 62 prostate cancer AIPC 62 Dasatinib 62 placebo controlled clinical 62 receptor tyrosine kinase inhibitor 62 metastatic CRPC 62 Panitumumab 62 bevacizumab Avastin ® 62 BrachySil TM 62 p# biomarker 62 XYOTAX TM 62 orBec 62 vismodegib 62 TOCOSOL Paclitaxel 62 evaluable 62 APTIVUS r 62 MEK inhibitor RDEA# 62 VNP#M 62 Voreloxin 62 Phase IIa trials 62 Triolex 62 generation purine nucleoside 62 MabCampath 62 SinuNase TM 62 ruxolitinib 62 UVIDEM 62 metastatic RCC 62 eribulin mesylate 62 MOZOBIL 62 metastatic colorectal 62 PANVAC VF 62 unresectable 62 surrogate endpoint 62 denufosol 62 mCRC 62 TBC# 62 vascular disrupting agent 62 ADVEXIN 62 Gliadel Wafer 62 chemoradiotherapy 62 CIMZIA TM certolizumab pegol 62 thymalfasin 62 Urocidin 62 oxymorphone ER 62 otelixizumab 62 GVAX immunotherapy 62 NV1FGF 61 Diamyd ® 61 Benlysta belimumab 61 Dacogen 61 GLPG# 61 gemcitabine Gemzar ® 61 atrasentan 61 Annamycin 61 cannabinor 61 sorafenib tablets 61 C1 INH 61 mTOR inhibitor 61 Actilon 61 ImClone Erbitux 61 Seliciclib 61 ToGA 61 APF# 61 erlotinib Tarceva 61 eritoran 61 ozarelix 61 LibiGel Phase III 61 PROSTVAC TM 61 AeroLEF TM 61 bosentan 61 Alpharadin 61 Irinotecan 61 refractory APL 61 Tesetaxel 61 antitumor activity 61 gemcitabine cisplatin 61 AZD# 61 Theratope 61 LAF# 61 pharmacodynamic PD 61 dacarbazine 61 infusional 5-FU/LV 61 Zelrix 61 ENMD 61 gefitinib 61 mitoxantrone plus 61 Albuferon 61 atacicept 61 dose escalation phase 61 MYDICAR ® 61 metastatic malignant melanoma 61 ANA# 61 docetaxel Taxotere 61 TYKERB 61 canakinumab 61 pivotal Phase 61 INCB# [002] 61 GED aPC 61 IMC #B 61 Safinamide 61 TRIOLEX 61 estramustine 61 intermittent dosing 61 Phase Ib clinical trials 61 PREZISTA r 61 EndoTAG 61 Hsp# Inhibitor 61 Pirfenidone 61 Torisel 61 Herceptin trastuzumab 61 recurrent ovarian cancer 61 evaluating Xcytrin 61 refractory chronic lymphocytic 61 metastatic pancreatic 61 opioid induced bowel dysfunction 61 seliciclib CYC# 61 free survival PFS 61 TRO# 61 LEUKINE 61 advanced carcinoid 61 Phase III randomized controlled 61 DAVANAT 61 interferon alfa 61 omacetaxine 61 refractory NSCLC 61 SAR# [004] 61 sunitinib Sutent 61 trabedersen 61 NEUVENGE 61 gemcitabine carboplatin 61 cobiprostone 61 Revlimid lenalidomide 61 R sorafenib tablets 61 rilonacept 61 Gattex 61 sipuleucel T 61 MAXY G# 61 prospectively defined 61 ApoB SNALP 61 subcutaneous formulation 61 initiate Phase 1b 61 metastatic GIST 61 ximelagatran 61 IIa trial 61 CRMD# 61 Ereska 61 rALLy trial 61 Increlex ® 61 GEM OS1 61 clazosentan 61 PD LID 61 DXL# 61 lixisenatide 61 midstage clinical 61 panitumumab Vectibix 61 velafermin belinostat 61 Ambrisentan 61 trastuzumab emtansine T DM1 61 posaconazole 61 SCCHN 61 CANCIDAS 61 liposomal formulation 61 Symadex 61 PROSTVAC ® 61 BLP# Liposome Vaccine 61 Bortezomib 61 systemic anaplastic large 61 trodusquemine 61 oral methylnaltrexone 61 GOUT 61 neoadjuvant treatment 61 Restanza 61 paclitaxel carboplatin 61 nonsmall cell lung cancer 61 MyVax R 61 Gemzar ® 61 Canvaxin TM 61 locoregional 61 fluoropyrimidine 61 plus DOXIL 61 varespladib 61 bafetinib 61 adalimumab 61 Onco TCS 61 androgen independent 61 virus HCV protease inhibitor 61 Civacir 61 Laquinimod 61 PREOS 61 sapacitabine CYC# 61 Phase IIb clinical trials 61 patients evaluable 61 resminostat 61 entinostat 61 EDEMA4 61 ILLUMINATE 61 budesonide foam 61 locoregional disease 61 rALLy 61 median PFS 61 multiple ascending dose 61 irinotecan chemotherapy 61 fosbretabulin 61 AGILECT R 61 Specifid 61 levosimendan 61 PF # [002] 61 Gabapentin GR 61 Gleevec imatinib mesylate 61 recurrent metastatic 61 BR.# 61 hypoxia activated prodrug 61 liver metastases 61 JAK3 61 melphalan prednisone 61 refractory acute myeloid 61 SYMMETRY trial 61 cetuximab Erbitux ® 60 squamous histology 60 investigational compound 60 Phase III clinical trials 60 cetuximab 60 IFN α 60 PRX# 60 favorable pharmacokinetic profile 60 Omnitarg 60 TroVax ® 60 Xelox 60 stage IIIB IV 60 Ceplene/IL-2 60 interferon ribavirin 60 Factor VIIa 60 RAD# [003] 60 Forodesine HCl 60 docetaxel prednisone 60 abiraterone 60 stage IIIB 60 paclitaxel poliglumex 60 LY# [003] 60 AEZS 60 imatinib therapy 60 TNF antagonist 60 erlotinib Tarceva ® 60 diabetic neuropathic pain 60 lenalidomide Revlimid R 60 carboplatin 60 evaluating Actimmune 60 ataluren 60 GvHD 60 SCH # 60 Nplate 60 pegylated interferon alfa 2b 60 Darusentan 60 CRLX# 60 AZOR 60 progression TTP 60 cutaneous T cell 60 RE SURGE 60 fostamatinib 60 anti EGFR antibody 60 #D#C# 60 non squamous NSCLC 60 DAPT 60 Ophena TM 60 Cloretazine R 60 Meets Primary Endpoint 60 Initiate Phase 60 dose escalation 60 GSK# [002] 60 phase III ACCLAIM 60 TKM ApoB 60 HCV RESPOND 2 60 GW# [003] 60 RhuDex ® 60 BZL# 60 refractory prostate cancer 60 rapid virologic response 60 CRD5 60 enoximone 60 mitomycin 60 pemetrexed Alimta 60 subcutaneous PRO 60 oral Hycamtin 60 PegIFN RBV 60 Apaziquone 60 Rezular 60 #mg/m# [001] 60 edoxaban 60 ofatumumab HuMax CD# 60 Dyloject TM 60 sorafenib 60 Azedra TM 60 refractory indolent non 60 Arcalyst 60 Aloxi injection 60 trabectedin 60 #I TM# 60 Elocalcitol 60 OncoVEX 60 FASLODEX 60 INCB# [003] 60 veltuzumab 60 Navelbine ® 60 Pivotal Trial 60 rHuPH# 60 Panzem NCD 60 Aptivus ® 60 AZILECT R 60 PKC# 60 capecitabine Xeloda R 60 Neuvenge 60 refractory metastatic colorectal cancer 60 gastrointestinal stromal tumor GIST 60 FTY# 60 pharmacokinetics PK 60 imatinib Gleevec ® 60 bortezomib Velcade R 60 NGX# 60 epratuzumab 60 Fibrillex 60 active comparator 60 bendamustine 60 SPRYCEL ® 60 randomized Phase III 60 Phase III 60 TASKi2 60 MAP# 60 ATL/TV# 60 confirmatory Phase 3 60 Neurodex 60 Median progression 60 octreotide LAR 60 FavId 60 CLL SLL 60 tolevamer 60 relapsing remitting multiple sclerosis 60 Omigard 60 PROCHYMAL 60 TG# [001] 60 biliary tract cancer 60 lesinurad 60 glioblastoma multiforme GBM 60 Elagolix 60 sitaxsentan 60 tocilizumab 60 Chrysalin 60 PTK ZK 60 ATACAND 60 Riquent 60 EDEMA3 60 Targretin capsules 60 Dendreon Provenge 60 pradefovir 60 Afatinib 60 bardoxolone methyl 60 FOLFOX6 60 Catena ® 60 interferon gamma 1b 60 dextromethorphan quinidine 60 GRN#L 60 trial evaluating Prochymal 60 BRAF V# mutation 60 Sulonex 60 orally bioavailable 60 ambrisentan 60 APTIVUS 60 Nasulin 60 proteasome inhibitor 60 midstage trials 60 Diabetic Macular Edema DME 60 recurrent GBM patients 60 INC# 60 TLK# 60 aleglitazar 60 Enzastaurin 60 tecarfarin 60 myelodysplastic syndromes MDS 60 BLA filing 60 BrachySil 60 Panzem R 60 PEG IFN 60 alfimeprase 60 eprotirome 60 synthetic retinoid 60 ENDEAVOR III 60 ProLindac 60 Zarnestra 60 IMPACT IMmunotherapy 60 BENLYSTA ® 60 Taxotere docetaxel 60 paclitaxel Taxol R 60 SinuNase ™ 60 erlotinib 60 BEXXAR 60 demonstrated antitumor activity 60 AVOREN 60 odanacatib 60 thetreatment 60 Mozobil 60 PRECISE trial 60 Ceflatonin ® 60 dirucotide MBP# 60 aclidinium bromide 60 tremelimumab 60 Exelixis XL# 60 EXPAREL TM 60 davunetide intranasal AL 60 Plenaxis TM 60 HBeAg positive patients 60 Rituxan rituximab 60 mycophenolate mofetil 60 taxane chemotherapy 60 ALN VSP 60 viral kinetics 60 ERBITUX 60 certolizumab 60 tubulin inhibitor 60 AVE# 60 Xinlay 60 Nexavar ® 60 tesetaxel 60 evaluating T DM1 60 including eniluracil ADH 60 ThermoDox R 60 HuMax CD# 60 maximally tolerated dose 60 Tarvacin 60 EMPHASIS HF trial 60 iroxanadine 60 pan HDAC inhibitor 60 aflibercept VEGF Trap 60 TYSABRI natalizumab 60 Synavive 60 Nexavar sorafenib 60 paclitaxel Taxol ® 60 peg interferon 60 indibulin 60 E2F Decoy 60 GLP toxicology studies